SCHEMBL5367619

SCHEMBL5367619

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1ccc(OC)c(C(C)(C)C)c1)C(=O)N2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 5/20 0.68
EGFR P00533 3/20 0.68
PSEN1 P49768 2/20 0.52
PSEN2 P49810 2/20 0.52
APH1B Q8WW43 2/20 0.52
NCSTN Q92542 2/20 0.52
APH1A Q96BI3 2/20 0.52
PSENEN Q9NZ42 2/20 0.52
SYK P43405 2/20 0.51
NTRK1 P04629 1/20 0.51
FCER2 P06734 1/20 0.51
NTRK3 Q16288 1/20 0.51
NTRK2 Q16620 1/20 0.51
SRC P12931 2/20 0.49
CDK2 P24941 2/20 0.48
KDR P35968 1/20 0.47
NOX4 Q9NPH5 1/20 0.46
RET P07949 3/20 0.44
FLT3 P36888 1/20 0.44
IGF1R P08069 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359504 0.89 PSEN1 (0.56) ERBB2EGFRPSEN1PSEN2APH1B
SCHEMBL5368923 0.88 ERBB2 (0.59) ERBB2EGFRSYKNTRK1FCER2
SCHEMBL7138911 0.87 NTRK1 (0.54) ERBB2EGFRPSEN1PSEN2APH1B
SCHEMBL5363020 0.86 ERBB2 (0.54) ERBB2EGFRPSEN1PSEN2APH1B
SCHEMBL7140225 0.86 NTRK1 (0.53) ERBB2EGFRPSEN1PSEN2APH1B
SCHEMBL7139502 0.86 NOX4 (0.54) ERBB2EGFRPSEN1PSEN2APH1B
SCHEMBL5363069 0.86 SRC (0.51) ERBB2EGFRSYKNTRK1FCER2
SCHEMBL5369597 0.85 ERBB2 (0.61) ERBB2EGFRPSEN1PSEN2APH1B
SCHEMBL5373158 0.84 ERBB2 (0.59) ERBB2EGFRPSEN1PSEN2APH1B
SCHEMBL5362073 0.84 ERBB2 (0.70) ERBB2EGFRSYKNTRK1FCER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ERBB2 19/4885EGFR 286/4885PSEN1 3695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.